Effect of pantoprazole and Helicobacter pylori therapy on uninvestigated dyspeptic patients
| Autor: | Hakan Senturk, Mukaddes Tozlu, Yusuf Kayar, Mehmet Sait Bugdaci, Ali Tüzün Ince, Omar Masri, Elif Arabaci, Birol Baysal, Omer Uysal |
|---|---|
| Přispěvatelé: | ŞENTÜRK, HAKAN |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.drug_class Population Proton-pump inhibitor Placebo Gastroenterology 2-Pyridinylmethylsulfinylbenzimidazoles Young Adult Pharmacotherapy Recurrence Clarithromycin Internal medicine Clinical endpoint medicine Humans Dyspepsia education Pantoprazole education.field_of_study Helicobacter pylori biology business.industry Amoxicillin Middle Aged Anti-Ulcer Agents biology.organism_classification bacterial infections and mycoses Anti-Bacterial Agents BAYSAL B. Senturk H. MASRI O. TOZLU M. KAYAR Y. ARABACI E. Uysal O. BUGDACI M. S. Ince A. T. -Effect of pantoprazole and Helicobacter pylori therapy on uninvestigated dyspeptic patients- TURKISH JOURNAL OF GASTROENTEROLOGY cilt.26 ss.6-14 2015 Treatment Outcome Drug Therapy Combination Female business medicine.drug |
| Popis: | Background/Aims: This study aimed to test the efficacy of empirical proton pump inhibitor use and Helicobacter pylori therapy for uninvestigated dyspepsia in a population with a high prevalence of H. pylori. Material and Methods: The study had a two-stage design. In the first stage, the efficacy of 4-week pantoprazole treatment was compared with placebo in patients with uninvestigated dyspepsia. In the second stage, the efficacies of 2-week treatment with pantoprazole in H. pylori-negative patients and H. pylori eradication therapy (pantoprazole + amoxicillin + clarithromycin) in H. pylori-positive patients were compared. The primary endpoint was sufficient overall symptom relief (Global Overall Symptom score ≤2; no or minimal symptoms) at the end of treatment. Results: In the first stage, sufficient overall symptom relief was achieved by 25.2% of patients in the pantoprazole group and 15.5% of patients in the placebo group, a difference that was not statistically significant (p=0.06). In the second stage, the rate of sufficient overall symptom relief was higher in the H. pylori therapy group than in the pantoprazole group (37.1% vs. 23.4%; p=0.02). After untreated follow-up, sufficient overall symptom relief remained significantly higher in the H. pylori therapy group than in the pantoprazole group (39.7% vs. 18%; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|